MannKind Corp. (MNKD), Monday announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application for Afrezza (insulin human) Inhalation Powder for the treatment of type 1 or type 2 diabetes in children and adults.
The application has been assigned a Prescription Drug User Fee Act or PDUFA target action date of May 29, 2026.
The approval is based on the Phase 3 INHALE-1 study data, which evaluated Afrezza in combination with basal insulin vs. multiple daily injections with basal insulin.
The full findings of the study will be shared at the International Society for Pediatric and Adolescent Diabetes in early November.
In the pre-market hours, MNKD is trading at $4.99, up 2.14 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.